Introduction: What this comparison will and won’t do
If you’re weighing ketamine infusion vs nasal spray, you’re probably trying to answer a very human question: What’s the safest, most realistic way to feel better, and how quickly? This is a practical comparison of IV ketamine (infusion) with intranasal options (FDA-approved Spravato and compounded nasal spray). I’ll also touch IM (intramuscular) and oral ketamine for context, because patients often ask, “If the medicine is the same, why does the route matter?”
The route changes nearly everything you experience and what you can plan for: onset (often minutes vs. Longer), how long benefits tend to hold, side effects (dissociation, nausea, blood pressure spikes), and how closely you need to be monitored. It also shifts safety considerations, especially if you’ve complex medical issues, active substance use, or you’re tapering opioids or kratom. Our team sees this often in physician-led protocols, including situations where people are managing withdrawal symptoms and mental health stabilization at the same time.
A clear limitation up front: even strong studies can’t predict your response with certainty. This is evidence-based education, not individualized medical advice. In our Dr. Bruce Richman clinic in Quakertown, PA, we use personalized care and ASKP³-Certified ketamine care to match the delivery method to the person, not the other way around.
How ketamine works: mechanism and why delivery matters
Ketamine’s antidepressant and anti-suicidal effects don’t come from “more serotonin.” The short version of the mechanism of ketamine is NMDA receptor blockade, which briefly shifts glutamate signaling, increases AMPA activation, and triggers downstream changes like BDNF release and synaptic remodeling. That neuroplasticity piece is what patients often describe as “I can finally get unstuck”, sometimes before their thoughts fully catch up.
Here’s the key: delivery controls how reliably you can reach that window.
With IV ketamine, bioavailability is essentially 100%. Blood levels rise quickly and predictably, which is why infusions are often chosen when rapid relief is the priority (for example, severe depression with suicidal thinking, or when tight control over dosing matters). That predictability comes with a non-negotiable requirement: monitoring, vitals, mental status, and the ability to adjust in real time if someone becomes too dissociated or hypertensive.
Intranasal ketamine is different. Absorption through nasal mucosa is inherently variable, and technique matters more than most people expect: congestion, drip down the throat, spray angle, and even timing between sprays can change the dose you actually absorb. That variability can translate into “some sessions hit hard, some barely register,” especially with compounded sprays. Spravato is standardized and regulated, but it still depends on nasal absorption, so the experience can be less predictable than IV.
IM sits between them. It can reach high levels similar to IV, but the rise is usually a bit slower, and once it’s given, you can’t “dial” the dose mid-session. Oral has the lowest bioavailability because of first-pass metabolism, so it tends to be gentler and more prolonged, and it’s usually less useful for urgent symptom change.
The practical takeaway: this isn’t just convenience vs. Needles. It’s pharmacokinetics, and that drives efficacy, side effects, and how much supervision you need. That’s why clinics treating depression, anxiety, chronic pain, and dependency (including Suboxone & Kratom dependence and opioid & benzodiazepine dependence) rely on structured, physician-led protocols rather than “try it and see.”
For anyone tapering or worried about dependency and withdrawal symptoms, timing and medication combinations can change the risk profile. It’s worth reading our clinical discussion of Ketamine and suboxone interaction in kratom tapering.
Research is also moving toward real-world comparisons rather than ideology. A head-to-head effort is described in a Yale Medicine overview of a study comparing IV ketamine and esketamine nasal spray. The field’s direction is increasingly: not “which is best,” but “which fits this patient, with these goals, under these safety considerations.”
Key Takeaways
- IV delivers ~100% bioavailability and rapid peak effects, so it’s often used for urgent symptom relief.
- In this route comparison, IV tends to be more predictable, while intranasal absorption varies and can feel less consistent.
- Spravato requires REMS and post-dose observation, while compounded nasal sprays don’t, so ask about monitoring standards.
- Expect dissociation and temporary BP or HR increases, and plan an escort because you can’t drive afterward.
- Compare total costs including clinic time, observation, travel, and missed work since coverage varies widely by route.
- Bring your meds list, medical history, goals, and budget, then ask about dosing, maintenance frequency, and emergency protocols.
Delivery methods explained: IV, nasal spray, IM, and oral
Most people asking about routes are really asking two practical questions: How controlled is the dosing? and How much clinic time and monitoring does it require? The answer depends on the method, and on safety considerations tied to your medical history, current medications, and symptom severity.
IV infusion
IV ketamine is the most “dialed-in” option. Typical physician-led protocols use a single infusion for diagnostic/response testing, or more commonly a short series (often 4, 6 sessions over 2, 3 weeks), followed by maintenance as needed. Infusions usually run 40, 120 minutes, depending on dose strategy, side effects, and whether the target is rapid relief for depression/anxiety versus pain.
Monitoring is continuous (blood pressure, heart rate, mental status) in a clinical setting. That oversight matters because ketamine can temporarily raise blood pressure and cause dissociation, and because real-time titration can reduce intensity if someone is uncomfortable. In our Quakertown, PA practice, our team also plans transportation to and from the clinic, plus medical oversight for mental health and suicide risk reduction, and for complex cases like Suboxone & Kratom dependence, opiate & benzodiazepine dependence, chronic pain, cerebral palsy, and dementia.
Intranasal
Spravato is intranasal esketamine with an FDA-labeled schedule and mandatory REMS monitoring, meaning you dose in-clinic and remain under observation afterward. Compounded nasal ketamine is different: it’s not under the same REMS structure, and dosing can vary more between pharmacies and prescribers. If you want the “why” behind these differences, the neurobiology overview in Ketamine effects on brain and body neurobiological insights is a solid primer.
IM and oral/sublingual (practical, but different tradeoffs)
Intramuscular ketamine is commonly used when IV access is difficult or when a shorter appointment is needed. Onset is usually fast, but the curve can feel less “smooth” than an infusion because you can’t titrate minute-to-minute.
Oral ketamine (or sublingual lozenges) has lower bioavailability and a longer onset. Some patients use it for maintenance or in lower-resource settings, but effects can be less predictable. It also raises more questions about dependency, tapering, and withdrawal symptoms when used frequently without tight guardrails and individualized follow-up.
Logistically, most clinic-based options require an escort home and a longer visit than people expect (dosing plus recovery time). Maintenance frequency is individualized: some people need monthly touch-ups, while others go several months between sessions once neuroplasticity-driven gains stabilize.
Efficacy: what the evidence shows (head-to-head and indirect comparisons)
IV ketamine has the most consistent track record for rapid relief in treatment-resistant depression, particularly when the goal is to interrupt severe symptoms quickly and then build on that window with therapy, sleep repair, and medication optimization. Many trials and clinical series show meaningful symptom drops within hours to days. The honest caveat is durability: without a plan, benefits can fade, which is why maintenance sessions and broader mental health support often matter as much as the initial response.
Spravato (esketamine) also works, but it’s studied and delivered differently. The FDA-cleared model is adjunctive (paired with an oral antidepressant) and measured over weeks with a structured induction and maintenance schedule. For many patients, that standardized pathway, and the built-in follow-up, can be a meaningful advantage.
A challenge in comparing these routes is that true head-to-head data has been limited until recently. A large, widely discussed comparison reported by Harvard suggests IV ketamine produced greater overall symptom reduction by the final dose, while intranasal esketamine still delivered significant benefit for many patients (coverage of the head-to-head study from news.harvard.edu). That’s helpful context, but it doesn’t erase the individual factors that shape response: comorbid anxiety, trauma load, bipolar spectrum features, pain syndromes, and medication interactions.
Indirect comparisons and meta-analyses still tend to favor IV for speed and magnitude of effect in the short term. For example, a 2024 meta-analysis in the Journal of Affective Disorders reviewed dosing ranges and found IV ketamine showed antidepressant efficacy even at lower doses, with a dose-response signal around 0.5 mg/kg (meta-analysis on IV ketamine and intranasal esketamine from sciencedirect.com). At the same time, protocols across studies vary widely, infusion length, number of sessions, outcome measures, and follow-up windows, so it’s not perfectly apples-to-apples.
So where do IM and compounded intranasal options land? Clinically, we do see benefit, sometimes dramatic, but the RCT-level evidence is thinner and dosing is less standardized. That variability is exactly why physician-led protocols and safety considerations matter, especially for patients with substance-use histories where monitoring for dependency, structured tapering, and watching for withdrawal symptoms isn’t optional.
To make this less abstract, here’s what “fit” can look like in real life. One patient with severe depression and panic who’d failed multiple medications responded after the second IV session, but the gains didn’t truly s
tick until maintenance was spaced thoughtfully and psychotherapy was coordinated. Another patient did better with intranasal esketamine because the repeated, scheduled visits kept them engaged when motivation was low. Same tool family, different match.
If you’re choosing based on “what works best,” the more accurate question is: which method matches your risk profile, your schedule, and the kind of follow-up you’ll realistically do? That’s where personalized care usually beats chasing the most impressive headline number.
Safety and side effects by route
Is it going to feel intense, and how controlled is the process? That’s the safety question hiding underneath most route decisions.
Across routes, the common acute side effects are consistent: dissociation (feeling detached), perceptual changes, dizziness, nausea, and a temporary bump in blood pressure and heart rate. Intensity usually tracks with peak blood levels, so faster-onset routes tend to feel “stronger” in the moment. That isn’t automatically bad. It does mean monitoring matters.
More serious risks are less common, but they’re the ones responsible clinics plan around. Misuse is a major concern, especially for anyone with a substance-use history or active worries about dependency, tapering, or withdrawal symptoms from other medications. A controlled, physician-led setting lowers that risk substantially. Rare adverse events can include severe hypertension, fainting, or prolonged confusion. And with very high cumulative exposure over time, there’s concern about cognitive effects and bladder irritation. Those bladder issues are far more associated with heavy recreational use than clinic-based care, but we still track total exposure and outcomes, because prevention is easier than repair.
Route-specific safety is where differences become practical:
- IV (and IM) dosing is the most controllable. We can adjust the rate, pause, or stop if side effects ramp up, and the peak is predictable. That’s one reason our team emphasizes Safer Ketamine Therapy with Precise Dosing as a core part of physician-led protocols.
- Intranasal esketamine (Spravato) has built-in guardrails. The FDA requires in-clinic dosing with post-dose observation because dissociation and sedation can impair judgment, and patients can’t drive afterward. That’s baked into the Spravato REMS program.
- Oral and lozenge-style options tend to be less predictable in absorption, which can mean uneven effects and harder-to-standardize safety considerations.
Contraindications and cautions are real: uncontrolled hypertension, certain cardiac conditions, and active psychosis are red flags. Pregnancy is typically a “pause and reassess” situation, not something to push through casually.
In practice, good monitoring looks boring, and that’s the point. Expect pre-treatment screening, baseline vitals, repeat BP/HR checks, clear emergency protocols, and tight documentation. At our ASKP³-certified clinic in Quakertown, PA, we do this daily for mental health (ADD, anxiety, depression, suicide risk reduction) and more complex cases like chronic pain, cerebral palsy, dementia, and opioid/benzodiazepine dependence (including Suboxone and kratom dependence), with transportation to and from the clinic when needed.
Cost, insurance, and access: real-world considerations
A hard fact: cost and logistics often decide the “winner” before preference ever gets a vote.
Typical ranges vary by region and protocol, but these are realistic ballparks:
| Option | What you usually pay for | Typical real-world cost pattern |
|---|---|---|
| IV ketamine infusion | Clinic time + medication + monitoring | Commonly priced per session, then discounted as a 6, 8 session series |
| IM ketamine | Injection + monitoring | Often cheaper than IV because there’s less equipment/time |
| Spravato (esketamine) | Drug + administration + required observation | Higher sticker price, but sometimes partially covered due to FDA approval and REMS structure |
| Compounded nasal ketamine | Medication (often cash-pay) + follow-ups | Lower drug cost, but coverage is inconsistent and many pay out-of-pocket |
| Oral/sublingual | Medication + visits | Usually lower cost, but less predictable effects can mean more trial-and-error |
Insurance is the big divider. Spravato has a clearer path because it’s FDA-approved for treatment-resistant depression (and requires Spravato REMS), so many plans cover it with prior authorization. IV ketamine and compounded options are still frequently out-of-network or cash-pay, and coverage is highly variable. One economic analysis looked at cost-effectiveness of esketamine compared with IV ketamine (PubMed), which is useful context when you’re weighing total spend against outcomes and time.
Hidden costs add up quickly: the mandatory observation window, needing an escort, transportation, and missed work hours. Access can be its own hurdle too, especially in rural areas where certified clinics are sparse and waitlists get long.
When you call a clinic, ask for an all-in estimate, not just “per dose.” Get clarity on monitoring time, what happens if you need to pause a session, and what documentation they’ll provide for insurance appeals. In our Quakertown practice, we’re used to building those packets because patients are juggling real budgets alongside mental health needs, and they deserve personalized care that’s financially realistic.
Patient experience and tolerability: what to expect during and after treatment
Picture two timelines. With IV, most people feel the shift during the infusion itself, often within minutes, and clinicians can fine-tune the dose in real time. With intranasal esketamine (Spravato), the onset can be less predictable: some patients feel it in 10, 20 minutes, others closer to 40, and absorption varies with congestion, technique, and anatomy.
Dissociation is common with both, but the “shape” differs. Infusions often feel smoother and more controllable because dosing is guided start-to-finish, while nasal dosing can arrive in waves. Environment matters more than people expect: a quiet room, low light, an eye mask, and a staff member who knows when to talk, and when to stay quiet, can change tolerability dramatically. Some patients feel anxious in their first session and then settle by session two once they understand the sensations aren’t dangerous.
Recovery time isn’t identical either. Plan on no driving after either route, and assume you’ll need an escort and downtime. Many people feel close to baseline within 2, 4 hours, but some have lingering fogginess up to 24 hours, especially if they’re sensitive to sedating medications or didn’t sleep well.
Emotionally, you might feel a cathartic “release,” or a brief mood wobble later that day. That’s why we treat ketamine therapy as more than a medication event: integration support and therapy help convert rapid relief into durable change through neuroplasticity. Practical prep helps: hydrate, skip heavy meals for 4, 6 hours, bring headphones or a blanket, and arrange transportation (we offer rides to and from our Quakertown, PA clinic for safety considerations, especially for patients dealing with mental health symptoms or pain). If you’re exploring pain indications too, we often point patients to Ketamine for chronic pain a non opioid option as a starting place.
Quick snapshot: what “day-of” typically feels like
| What you’re comparing | IV ketamine infusion | Intranasal esketamine (Spravato) |
|---|---|---|
| Onset | Often within minutes | Variable, commonly 10, 40 min |
| Dissociation | Typically smoother, dose can be adjusted | Can be “wave-like,” less controllable once dosed |
| Monitoring | Continuous, clinic-based | Clinic-based monitoring required |
| Usual same-day restrictions | No driving, rest afterward | No driving, rest afterward |
| Common patient experience | “Guided” and predictable | Convenient, but sometimes inconsistent |
How to choose: decision framework for patients and clinicians
What are you trying to change first, immediate safety, day-to-day functioning, or long-term relapse prevention? If you’re asking how to choose ketamine, start with the clinical goal, not convenience. When someone needs urgent symptom reduction, severe depression, active suicidality, or marked agitation, IV is often favored because clinicians can deliver a precise dose and adjust it in real time while continuously monitoring vital signs. That moment-to-moment control is one reason many comparisons in the ketamine infusion vs nasal spray discussion lean toward IV for speed and magnitude of response, including a 2024 meta-analysis on dosing and outcomes in research on IV ketamine vs intranasal esketamine published by ScienceDirect.
Maintenance is a different problem. For ongoing support, adjunctive treatment, or when a patient strongly prefers a less invasive option, intranasal therapy can be a good fit, provided the clinic’s structure and follow-up are strong. Many protocols begin with an induction phase (often twice weekly for several weeks for REMS-based intranasal esketamine) and then step down to weekly or every-other-week visits if symptoms stabilize. Some patients do best with a blended plan: an IV series for stabilization, followed by a maintenance strategy with careful spacing and tapering when appropriate.
Safety considerations usually matter more than patients expect. Uncontrolled hypertension, significant cardiac history, pregnancy, and certain medication interactions can change the route, timing, or whether treatment should be delayed. Substance use history also deserves a frank, nonjudgmental conversation, not because ketamine automatically causes dependency, but because the wrong setting and poor follow-up can increase the risk of misuse or rebound symptoms when people try to self-medicate outside physician-led protocols.
Logistics and values count, too: budget, travel time, and whether you want a tightly supervised experience versus a more standardized observed protocol. At Dr. Bruce Richman’s ASKP³-Certified Ketamine Care clinic in Quakertown, PA, our team builds personalized care plans for patients with ADD, anxiety, depression, cerebral palsy, dementia, chronic pain, and complex dependence histories (including Suboxone & kratom dependence, and opiate & benzodiazepine dependence), with medical monitoring and suicide risk reduction built into the plan.
A practical treatment decision checklist
- Goal: rapid relief now, or steady maintenance over time?
- Route fit: which ketamine delivery option matches your medical history and risk profile?
- Monitoring: do you need tighter titration and continuous vitals (IV), or a standardized observed protocol (intranasal)?
- Cost and time: how many visits can you realistically do, and what’s your travel burden?
- Support: do you’ve therapy/integration in place to turn symptom improvement into lasting change?
Case examples: realistic scenarios and recommended approaches
Vignette 1: severe suicidal ideation and the need for speed
A patient once described it this way: “I don’t need perfect, I need tomorrow to be survivable.” Imagine a 34-year-old with treatment-resistant depression reporting active suicidal ideation, unable to guarantee safety at home, after multiple medication trials. This is one of the clearest Spravato scenarios where people ask about ketamine infusion vs nasal spray, but the clinical priority is rapid, reliable dosing and close observation. In practice, that often means choosing IV in a monitored, physician-led setting, especially when you need fast symptom relief and tight safety oversight.
A large head-to-head comparison reported stronger symptom reduction with IV by the end of a treatment course (Mass General Brigham’s ketamine vs esketamine comparison), which matters when time is the enemy. Ketamine therapy may also support neuroplasticity, but it isn’t a standalone fix; you still need a safety plan, aftercare, and clear follow-up.
3 next steps
- Same-week evaluation with suicide risk reduction planning and a support person involved.
- Start physician-led protocols with monitored dosing and a plan for maintenance.
- Pair treatment with psychotherapy within 1 to 7 days.
2 questions to ask your provider
- “What’s your emergency procedure if my symptoms worsen after treatment?”
- “How will you decide maintenance frequency once I respond?”
Vignette 2: history of hypertension and cardiac risk
Here’s a hard clinical fact: both IV ketamine and intranasal esketamine can cause short-lived increases in blood pressure and heart rate. Consider a 58-year-old with poorly controlled blood pressure who wants relief from anxiety and depression but has had prior ER visits for hypertensive spikes. In this situation, the “best” route is the one your clinician can monitor and adjust safely. Sometimes that means tightly supervised IV with continuous vitals; other times it means stabilizing medical issues first. Occasionally, the safest decision is choosing a different treatment until cardiac risk is better controlled.
The downside is straightforward: if baseline numbers are unsafe, neither route is “gentle.” Good care looks like individualized screening, pre-treatment clearance when indicated, and a conservative start with clear stop-criteria.
3 next steps
- Bring recent BP logs and cardiology notes. Don’t rely on memory.
- Ask about pre-treatment thresholds (for example, “we won’t treat above X/Y”) and what happens if readings rise mid-session.
- Review stimulating meds and decongestants, and discuss whether any tapering is appropriate (only under supervision).
2 questions to ask your provider
- “What BP range do you require before dosing, and who’s monitoring during and after?”
- “If I’ve chest tightness or a severe headache, what’s the protocol on-site?”
Vignette 3: remote, limited budget, and access barriers
Access can be the deciding factor long before efficacy is. Picture a 29-year-old who lives 2 hours away, can’t miss work often, and is worried about cost. In real-world case examples, this is where the conversation expands beyond IV vs FDA-cleared intranasal esketamine. Some people explore oral options, compounded nasal formulations (where legal and clinically appropriate), telehealth-supported follow-ups, or sliding-scale programs. The goal is access without cutting corners on safety, especially around misuse risk, medication interactions, and the possibility of withdrawal symptoms if other substances are involved.
When someone is also dealing with Suboxone & Kratom dependence or opiate & benzodiazepine dependence, the plan has to include stabilization, monitoring, and relapse prevention, not just symptom relief. For a straight-shooting overview that clears up common misunderstandings, we often point people to Debunking ketamine therapy myths facts and insights early in the decision process.
3 next steps
- Ask for a transparent cost map (induction, maintenance, transport, missed-work time).
- Explore transportation support and consolidated visit schedules.
- Coordinate mental health follow-up locally (therapy, PCP, psychiatry).
2 questions to ask your provider
- “What’s the lowest-visit plan you can do without sacrificing monitoring?”
- “How do you screen for misuse risk, dependency, and interactions with my current meds?”
Summary, practical checklist, and questions to ask your provider
The core tradeoff in ketamine infusion vs nasal spray is control versus convenience. IV typically offers tighter dose control and continuous monitoring, which can matter for rapid relief, complex medical histories, or high-risk mental health presentations. Intranasal esketamine is more standardized and can be easier to access in some settings, but it still requires in-clinic observation, and cost and scheduling can surprise people. In practice, safety considerations, medical comorbidities, and your ability to commit to follow-up usually decide more than preference.
One honest caveat: the evidence base is still evolving. While meta-analyses and observational comparisons are helpful, truly definitive head-to-head trials are limited, and outcomes can vary substantially based on dosing, setting, and the quality of monitoring and aftercare.
Checklist to bring
- Full medical history (BP issues, seizures, sleep apnea, substance use history).
- Current meds and supplements (including stimulants, benzos, opioids, Suboxone, kratom).
- Goals and timeline (suicidality, function, sleep, pain, anxiety).
- Budget and logistics (time off work, transportation, childcare).
Questions to ask and next steps
- “What dose range do you use, and how do you adjust it session to session?”
- “What monitoring happens during treatment, and what are your emergency procedures?”
- “What’s the benefits timeline you expect for me, week 1 vs week 4?”
- “How do you handle side effects, and what would make you pause treatment?”
- “What’s your maintenance plan, and how do you taper safely if we stop?”
If you’re choosing a clinic, prioritize physician-led protocols, clear screening for misuse risk, and coordination with psychotherapy. Our team in Quakertown, PA also builds plans for ADD, Anxiety, Depression, Cerebral Palsy, Dementia, chronic pain, and substance dependence, with transportation to and from clinic and structured medical follow-up.
Frequently Asked Questions
Is IV ketamine more effective than nasal spray?
It can be, often IV ketamine appears more consistently potent and faster-acting than intranasal options, but the best choice depends on your situation. Meta-analyses and RCTs generally show IV ketamine can produce rapid, strong short-term antidepressant effects within hours to days, while direct head-to-head comparisons with intranasal esketamine are limited and results are mixed. Esketamine (Spravato) is FDA-approved for treatment-resistant depression as an add-on to an oral antidepressant. Response varies by diagnosis, dosing schedule, and clinic protocol, so this isn’t one-size-fits-all.
How long do the effects last for infusion vs nasal spray?
IV ketamine can relieve symptoms within hours, and a single infusion may last days to a couple of weeks, though many people need a series for more durable benefit. Spravato tends to build benefit with repeated dosing and can be continued as maintenance (often weekly to every-other-week after an induction phase). Other routes like IM or oral lozenges can vary widely in onset and duration. Most plans require follow-up and a maintenance protocol if symptoms return.
Which option is safer for people with heart conditions?
Neither option is automatically “safer” for heart conditions because ketamine can transiently raise blood pressure and heart rate regardless of route. If you’ve uncontrolled hypertension, arrhythmias, recent cardiac events, or severe vascular disease, you’ll need careful screening and may need cardiology input before treatment. Choose a setting with medical monitoring, especially when comparing IV and intranasal approaches, since at-home routes may be inappropriate. Checklist: share your cardiac history and meds, get baseline BP, ensure on-site vitals monitoring, and have a plan for managing spikes.
Will my insurance cover Spravato or IV ketamine?
Insurance is more likely to cover Spravato than IV ketamine because Spravato is FDA-approved and dispensed under a REMS program, but coverage still varies by plan. Many insurers require prior authorization, proof of treatment-resistant depression, and documentation that it’s used with an oral antidepressant in a certified clinic. IV ketamine and compounded nasal sprays or IM injections are often cash-pay. Steps: ask the clinic for billing codes and medical-necessity notes, request a denial letter, and file an appeal.
Can ketamine cause addiction or long-term cognitive problems?
Yes, ketamine can be addictive and may cause cognitive or bladder problems with heavy, repeated use, but supervised medical treatment appears to carry a much lower risk than recreational misuse. Most concerns come from high-dose, frequent exposure over long periods, which has been linked to urinary symptoms and memory or attention issues. In clinics, dosing is controlled and patients are monitored for side effects and escalating use. You should still discuss substance-use history, track cumulative exposure, and reassess risk versus benefit over time.
References
- “Yale-Led Study Will Compare Effectiveness of IV Ketamine .” (medicine.yale.edu) https://medicine.yale.edu/news-article/yale-led-study-will-compare-effectiveness-of-iv-ketamine-and-esketamine-nasal-spray/
- “First study to compare two ketamine therapies for patients .” (news.harvard.edu) https://news.harvard.edu/gazette/story/2025/09/first-study-to-compare-two-ketamine-therapies-for-patients-with-severe-depression/
- “Cost-effectiveness of esketamine nasal spray compared to .” (pubmed.ncbi.nlm.nih.gov) https://pubmed.ncbi.nlm.nih.gov/36162672/
- “Efficacy of intravenous ketamine and intranasal .” (sciencedirect.com) https://www.sciencedirect.com/science/article/abs/pii/S0165032724005615
- “Study Finds Two Forms of Ketamine Therapy Can Reduce .” (massgeneralbrigham.org) https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/ketamine-esketamine-comparison-study
- “IV Ketamine vs. Esketamine: Harvard’s 2025 Study Settles .” (vanguardbehavioral.com) https://vanguardbehavioral.com/blog/iv-ketamine-vs-esketamine-harvard-study/
- “IV Ketamine vs. Nasal Esketamine for Treatment-Resistant .” (innerbloomketamine.com) https://innerbloomketamine.com/blog/iv-ketamine-vs-nasal-esketamine-for-treatment-resistant-depression-a-new-study-sparks-renewed-debate/
- “Ketamine Infusion vs. Nasal Spray in Treating Depression” (tranquilityketamine.com) https://tranquilityketamine.com/ketamine-infusion-vs-nasal-spray-in-treating-depression/
- “Study: Intravenous Ketamine Vs. Intranasal Esketamine” (psychiatrist.com) https://www.psychiatrist.com/news/study-intravenous-ketamine-vs-intranasal-esketamine/
- “How Is Spravato Nasal Spray Different Than Ketamine .” (haganhealth.com) https://haganhealth.com/how-is-spravato-nasal-spray-different-than-ketamine-infusion/